Duration of Humoral Immunity and Cross-Neutralizing Activity Against the Alpha, Beta, and Delta Variants After Wild-Type Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Prospective Cohort Study.

The Journal of Infectious Diseases Pub Date : 2022-09-21 DOI:10.1093/infdis/jiac050

Ji Yun Noh, Jeong Sun Yang, Soon Young Hwang, Hakjun Hyun, Hye Seong, Jin Gu Yoon, Soo Young Yoon, Hee Jin Cheong, Woo Joo Kim, Woo Jung Park, Jun Won Kim, Joo Yeon Lee, Joon Young Song

{"title":"Duration of Humoral Immunity and Cross-Neutralizing Activity Against the Alpha, Beta, and Delta Variants After Wild-Type Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Prospective Cohort Study.","authors":"Ji Yun Noh, Jeong Sun Yang, Soon Young Hwang, Hakjun Hyun, Hye Seong, Jin Gu Yoon, Soo Young Yoon, Hee Jin Cheong, Woo Joo Kim, Woo Jung Park, Jun Won Kim, Joo Yeon Lee, Joon Young Song","doi":"10.1093/infdis/jiac050","DOIUrl":null,"url":null,"abstract":"<p><p>A prospective cohort study was conducted for adults with a diagnosis of with coronavirus disease 2019 (COVID-19). Convalescent blood samples were obtained 4, 6, and 11 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19 diagnosis. Neutralizing antibody levels against wild-type SARS-CoV-2 gradually decreased but remained positive in >50% of patients 11 months after diagnosis: in 98.5% (67 of 68) at 4 months, 86.8% (46 of 53) at 6 months, and 58.8% (40 of 68) at 11 months. However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared with the wild-type strain.</p>","PeriodicalId":509652,"journal":{"name":"The Journal of Infectious Diseases","volume":" ","pages":"975-978"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903377/pdf/jiac050.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiac050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

A prospective cohort study was conducted for adults with a diagnosis of with coronavirus disease 2019 (COVID-19). Convalescent blood samples were obtained 4, 6, and 11 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19 diagnosis. Neutralizing antibody levels against wild-type SARS-CoV-2 gradually decreased but remained positive in >50% of patients 11 months after diagnosis: in 98.5% (67 of 68) at 4 months, 86.8% (46 of 53) at 6 months, and 58.8% (40 of 68) at 11 months. However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared with the wild-type strain.

查看原文本刊更多论文

野生型严重急性呼吸综合征冠状病毒2型感染后体液免疫持续时间和对α、β和δ变异的交叉中和活性:一项前瞻性队列研究

对诊断为2019冠状病毒病(COVID-19)的成年人进行了一项前瞻性队列研究。在严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染后4、6和11个月采集恢复期血液样本。所有患者抗刺突抗体血清阳性(100%)维持至新冠肺炎诊断后11个月。针对野生型SARS-CoV-2的中和抗体水平在诊断后11个月逐渐下降，但在>50%的患者中仍呈阳性:4个月时为98.5%(68人中67人)，6个月时为86.8%(53人中46人)，11个月时为58.8%(68人中40人)。然而，与野生型菌株相比，对β和δ变异的交叉中和活性分别减弱了2.53倍和2.93倍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of Infectious Diseases

自引率

0.00%

发文量